Results 291 to 300 of about 933,327 (380)

Addition of Phentermine‐Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double‐Blind Randomized Clinical Trial

Obesity, EarlyView.
ABSTRACT Objective This study compared the effects of phentermine‐topiramate‐ER (mid‐dose 7.5/46 mg) versus placebo on weight loss and cardiovascular disease (CVD) risk outcomes when used as an adjunct to a digitally enhanced lifestyle intervention (DELI).
Alejandro Campos, Wissam Ghusn, Lizeth Cifuentes, Daniel Sacoto, Sima Fansa, Diego Anazco, Maria L. Ricardo‐Silgado, Anas Hashem, Megan Schaefer, William S. Harmsen, Heather J. Gunn, Craig Peterson, Deborah Larsen, Santosh T. Varghese, Maria D. Hurtado, Andres Acosta   +15 more
wiley   +1 more source

Assessing the association between the non-HDL to HDL cholesterol ratio and NAFLD in Chinese adults: concentrate on gout populations. [PDF]

Front Nutr
Sun C, Si K, Zhu Y, Li C, Yu Y, Jia C, Wang Q.   +6 more
europepmc   +1 more source

The MetaboHealth Score Enhances Insulin Resistance Metabotyping for Targeted Fat Loss: The PERSON Study

Obesity, EarlyView.
ABSTRACT Objective We previously identified distinct muscle and liver insulin resistance (IR) metabotypes in middle‐aged and older adults. The PERSON study showed that a low‐fat, high‐protein, high‐fiber diet benefits the muscle IR group, while a high‐monounsaturated fatty acid diet benefits the liver IR group. We also developed the MetaboHealth score,
Jordi Morwani‐Mangnani, Fatih A. Bogaards, Alexander Umanets, Gabby B. Hul, Anouk Gijbels, Gijs H. Goossens, Joris Deelen, Marian Beekman, Lydia Afman, Ellen E. Blaak, P. Eline Slagboom   +10 more
wiley   +1 more source

Monocyte-to-HDL cholesterol ratio (MHR) as a novel Indicator of gout risk. [PDF]

Sci Rep
Mi L, He X, Gao J, Xu K.
europepmc   +1 more source

Clinical remission in newly diagnosed type 1 diabetes mellitus and HDL function on cholesterol efflux capacity: prospective InLipoDiab1 study

Aleksandra Uruska, Maja Miętkiewska-Dolecka, Agata Grzelka‐Woźniak, Justyna Flotyńska, Suzanne Saldanha, Anand Rohatgi, Dorota Zozulińska‐Ziółkiewicz   +6 more
openalex   +1 more source

PCV10 EFFECTS OF INTENSIFYING LIPID-ALTERING THERAPY ON CHD EVENTS IN A SECONDARY PREVENTION POPULATION WITH HIGH NON-HDL CHOLESTEROL

, 2008
J Menzin, B Zhang, Meyer Friedman, S.L. Charland, RT Burge   +4 more
openalex   +1 more source

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT

Obesity, EarlyView.
ABSTRACT Objective This post hoc analysis assessed psychiatric changes with tirzepatide in adults with obesity, without known major psychopathology, from SURMOUNT‐1, SURMOUNT‐2, and SURMOUNT‐3. Methods In participants (N = 4056) treated with tirzepatide (5/10/15 mg or maximum tolerated dose 10/15 mg) versus placebo, depressive symptoms and suicidal ...
Thomas A. Wadden, Maria A. Oquendo, Robert F. Kushner, Dachuang Cao, Chrisanthi A. Karanikas, Afton Kechter, Madhumita A. Murphy   +6 more
wiley   +1 more source

The relationship between non-HDL cholesterol to HDL cholesterol ratio (NHHR) and anemia: A cross-sectional study of NHANES, 2009 to 2016. [PDF]

Medicine (Baltimore)
Cao N, Wang J, Zhu J, Jiao X, An F, Zhai Z.   +5 more
europepmc   +1 more source

Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT‐1 Trial

Obesity, EarlyView.
ABSTRACT Objective This prespecified subpopulation analysis aimed to assess the efficacy and safety of once‐weekly tirzepatide versus placebo alongside lifestyle intervention in Japanese adults with obesity or overweight. Methods Data from 102 Japanese adults in the SURMOUNT‐1 trial with BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 and ≥ 1 weight‐related comorbidity ...
Yasushi Ishigaki, Masamichi Yamada, Tomotaka Shingaki, Tomonori Oura, Iichiro Shimomura   +4 more
wiley   +1 more source

Correction: U-shaped relationship between frailty and non-HDL-cholesterol in the elderly: a cross-sectional study. [PDF]

Front Nutr
Pan Y, Yuan Y, Yang J, Feng ZQ, Tang XY, Jiang Y, Hu GM, Dong JC.   +7 more
europepmc   +1 more source